Cargando…

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment

Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased over the last 30 years, with a plateau anticipated around the year 2030 in Western countries. Molecular MPM carcinogenesis involves alterations of NF2, RASSF1, LATS2WT1, p16, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gounant, Valérie, Brosseau, Solenn, Zalcman, Gérard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669877/ https://www.ncbi.nlm.nih.gov/pubmed/34917175 http://dx.doi.org/10.1177/17588359211061956

Ejemplares similares

Malignant Pleural Mesothelioma (MPM) Presenting as Hydropneumothorax
por: Kuramochi, Masami, et al.
Publicado: (2023)

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
por: Dubois, Fatéméh, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
por: Pagano, Maria, et al.
Publicado: (2020)

Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
por: Wright, Casey M., et al.
Publicado: (2013)

KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
por: Lorenzini, Eugenia, et al.
Publicado: (2022)

The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
por: Yuen, Man Lee, et al.
Publicado: (2021)

The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
por: Banerji, Shantanu, et al.
Publicado: (2021)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2021)

Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
por: Laure, Alexander, et al.
Publicado: (2023)

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients
por: Cedres, Susana, et al.
Publicado: (2023)

Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021)

In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM)
por: Singh, Anand S., et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

MA04.07 Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection
por: Cedres, S., et al.
Publicado: (2021)

A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma
por: Li, Wei, et al.
Publicado: (2023)

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
por: Cedrés, Susana, et al.
Publicado: (2015)

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
por: Mendoza, Tito R., et al.
Publicado: (2019)

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
por: Rozitis, Eric, et al.
Publicado: (2020)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
por: Gray, Steven G.
Publicado: (2021)

Current status and progress in immunotherapy for malignant pleural mesothelioma
por: Sun, Boyang, et al.
Publicado: (2022)

Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report
por: Pluvy, Johan, et al.
Publicado: (2019)

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2020)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

An appropriate choice for immunotherapy in malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2020)

Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures
por: Sarun, Kadir Harun, et al.
Publicado: (2018)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Immunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better?
por: Guo, Xiaotong, et al.
Publicado: (2023)

Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
por: Reid, Glen, et al.
Publicado: (2020)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study
por: Zauderer, Marjorie G, et al.
Publicado: (2021)

Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2
por: Kuwata, Taiji, et al.
Publicado: (2020)

Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy
por: Porta, Chiara, et al.
Publicado: (2023)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma
por: Vita, Emanuele, et al.
Publicado: (2021)

Immunotherapy in malignant pleural mesothelioma: a review of literature data
por: Menis, Jessica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kifjocn3febdmva2sc9399cl5s